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Katherine L Nathanson5,6 and William D Foulkes1,2,3,7*Abstract
Background: The RNase III enzyme DICER1 plays a central role in maturation of microRNAs. Identification of
neoplasia-associated germ-line and somatic mutations in DICER1 indicates that mis-expression of miRNAs in cancer
may result from defects in their processing. As part of a recent study of DICER1 RNase III domains in 96 testicular
germ cell tumors, a single RNase IIIb domain mutation was identified in a seminoma. To further explore the
importance of DICER1 mutations in the etiology of testicular germ cell tumors (TGCT), we studied germ-line DNA
samples from 43 probands diagnosed with familial TGCT.
Findings: We carried out High Resolution Melting Curve Analysis of DICER1 exons 2–12, 14–19, 21 and 24–27. All
questionable melt curves were subjected to confirmatory Sanger sequencing.
Sanger sequencing was used for exons 13, 20, 22 and 23. Intron-exon boundaries were included in all analyses. We
identified 12 previously reported single nucleotide polymorphisms and two novel single nucleotide variants. No likely
deleterious variants were identified; notably no mutations that were predicted to truncate the protein were identified.
Conclusions: Taken together with previous studies, the findings reported here suggest a very limited role for either
germ-line or somatic DICER1 mutations in the etiology of TGCT.
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Animals and plants express hundreds of miRNAs, which
are predicted to target and regulate at least 60% of
protein-coding mRNAs and are integral to almost all
known biological processes. DICER1 is highly conserved
throughout evolution, and contains several functionally
important domains. We and others have identified both
germ-line and somatic mutations in DICER1 that are as-
sociated with a range of mainly childhood-onset cancers
and dysontogenic or hyperplastic conditions, notably
“blastoma”-type tumors such as pleuropulmonary
blastoma (PPB), ovarian Sertoli- Leydig cell tumor* Correspondence: william.foulkes@mcgill.ca
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distribution, and reproduction in any medium(SLCT), embryonal rhabdomyosarcoma and Wilms
tumor, as well as benign tumors such as cystic nephroma
[1-10]. Despite a detailed study of hundreds of cancer
cell lines [4], the full extent and limit of the involvement
of both germ-line and somatic DICER1 mutations in
rarer types of human cancer is currently unknown.
A large study of all exons of DICER1, conducted using
DNA from 4 microsatellite-stable testicular germ cell
tumor (TGCT) cell lines and germ-line DNA from 185
persons with a germ cell tumor (of whom 71 had a
seminoma and 128 of whom had a family history of
TGCT) revealed one germ-line mutation, c.4740G > T,
p.Q1580H, in a man with a past personal history of
seminoma [4]. The mutation is of unknown significance,
but according to Polyphen2 [11], this mutation is pre-
dicted to be probably damaging with a score of 0.996
(sensitivity: 0.55; specificity: 0.98), and in agreement withntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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1580 from Q to H is predicted to affect protein function
with a score of 0.00 (less than 0.05 is usually regarded as
evidence for a deleterious effect on protein function).
Recurrent “hotspot” somatic mutations exist in the
RNase IIIb domain of DICER1 [10]. These hotspot mu-
tations were mainly identified in SLCT, but of 26 TGCT
analysed for the hotspots, a single non-seminomatous
TGCT was found to possess c.5125G > A, p.D1709N. It
could not be determined if the mutation was germ-line
or somatic in nature [10], but this mutation is func-
tionally deleterious [13] and therefore could be etio-
logically related to the occurrence of the TGCT.
Another study did not identify a DICER1 mutation in a
man with a seminoma, who was the relative of a pa-
tient with a PPB [5].
Recently, de Boer et al. reported finding only one pre-
sumed somatic RNase IIIb domain mutation (c.5174G >A;
p.R1725Q) among 96 TGCT for mutations in this do-
main [14]. Bioinformatic analysis of this variant gives
varying results; whereas Polyphen2 [11] suggests that
this mutation is predicted to be probably damaging
with a score of 1.000 (sensitivity: 0.00; specificity:
1.00), SiftBLink [12] reports that substitution at pos-
ition 1725 from R to Q is predicted to be tolerated
with a score of 0.18.
In view of these previous studies, we wished to estab-
lish if germ-line DICER1 mutations play a role in the eti-
ology of TGCT, with the clinical aim of better
counselling DICER1 mutation carriers as to their cancer
risks. We report here our analysis of germ-line DNA
from 43 probands with a personal and family history of
TGCT.Table 1 Type of testicular germ cell tumor in 39 probands# p
Type of testicular germ cell tumor in the proband 1st
Seminoma, NOS 5
Embryonal carcinoma, NOS 1
Teratoma, benign 0
Teratocarcinoma 1
Choriocarcinoma combined with other germ cell elements 0
Yolk sac tumor 0
Germ cell tumor, nonseminomatous 0
Mixed germ cell tumor (mixed teratoma and seminoma) 1
Mixed germ cell tumor (mixed embryonal and seminoma) 3
Mixed germ cell tumor (mixed yolk sac and seminoma) 0
NSGCT (mixed yolk sac and teratoma, benign) 0
*First degree- parent, sib, child; second degree - aunt, uncle, grandparent, grandchi
relative affected, only the closest degree of relatedness is included.
NSGCT – Non-seminoma germ cell tumor; NOS – not otherwise specified.
#Family history could not be confirmed for two cases (seminoma and yolk sac tumo
four cases were excluded from the table.Methods
Subjects
Men with TGCT were recruited through an on-going
case–control study at the Perelman School of Medicine
at the University of Pennsylvania, which has been previ-
ously described [15,16]. All patients completed a ques-
tionnaire, which includes self-reported information
about family history of TGCT. For the current study,
men with TGCT who reported a family history of at
least one relative also with TGCT were selected
(Table 1). All studies were carried out in accordance
with the Institutional Review Board (IRB) of the
University of Pennsylvania with written consent (IRB
study number: 703123).
Experimental details
We conducted High Resolution Melting Curve (HRM)
analysis of DICER1 [GENBANK NM_177438.2] exons
2–12, 14–19, 21, the 3’ half of 23 and 24–27 using
lymphocyte DNA from one proband from each family as
described previously [3]. Briefly, we screened 22 of the
26 coding exons of DICER1 by (HRM) using the
LightScanner instrument (Idaho Technologies Inc.,
Utah, USA). The PCR reactions were done in 96 well
plates from Bio Rad (Ontario, Canada) using the
mastermix and the LCGreen Plus from Transition Tech-
nologies (Ontario, Canada). The plates were then trans-
ferred to the LightScanner instrument and the melted
curves were analyzed by the software provided by
Idaho Technologies. This technique was used as a
presequencing selection for amplicons harboring vari-
ants. The PCR primers used are shown in Table 2. All
questionable melt curves were subjected to confirmatorylus degree of relatedness to familial case(s) of TGCT
Degree of relatedness to affected relative
2nd 3rd >3rd Total
3 4 0 12
3 1 1 6
0 1 0 1
0 2 2 5
0 2 0 2
0 1 0 1
0 1 0 1
1 0 0 2
1 2 0 6
0 0 1 1
0 1 0 1
ld; third degree – cousin; more than third – second cousin. If more than one
r) and pathology could not be fully confirmed on a further two cases. These
Table 2 DICER1 oligonucleotide primers used in this study






2 GCAATGAAAGAAACACTGGATG TCAAATCCAATTACCCAGCAG 358 [1] 64
3 TTTTGTAAATTTATTGGAGGACG TCTGCCAGAAGAGATTAAATGAG 429 [1] 64
4 TTTTGGAGGATAACCTTGGAAC AAATCAGACAACCAAGGCTACAG 390 [1] 66
5 TTGTCGTCAAGACATGCTTTC TTTAATATTCATTCATTCATACACTGC 518 [1] 66
6 TAGTGGCATTTCCACCAAAC GAATTCTTACTCTTGCCCATTCC 437 [1] 69
7 TTCTCACTACTGCAGTATTGATACCTT GAGCCGCATTAAGCATATTTTC 303 [1] (7 F modified) 69
8 AAATCCCAGTTAAACCCCAC TCACATCACAACACAGGACG 554 [1] 68
9 TAAATCACCGTCGCCAAATC AAATCACTCTACAGCTACCTCATGG 591 [1] 69
10 CATGTGTGTCAGAAATGACAGTTG TTCCTATGGATACAAAGAATAACAAAG 431 [1] 68
11 AGCAGGTTACTTTGGAGTACTGAAG AACTTTTATTGCTGCACGATACTG 498 [1] 69
12 TCACATTTCAAGTGCTCACC TGAACATGTAGATGACTACAAAAGC 596 [1] 69
13 TTTTACTAGGCAGGACTTTTAAAGATG AAGTGTTCATGGTGCATGATTC 585 [1] NA
14 TTTGCAGTCCAGCTCATATTG AAGCTGTGAATCGGAGAAAG 498 [1] 69
15 TAAGAAGTGTCATGCCTCGG TCTAGTGGAGAAATAGAAGAGGCAC 468 [1] 68
16 GAAAGCATCATTTCTGTTCTGAAG AAGAGAAAAACGACTCTTTAGC 443 16R is new 65
17 TTCAGCATACTGTGTTCTACCTCTT TTTTAGTAGAGACGAGGTTTCACC 484 17 F is new 69
18 TGTAAAGGTGCCATTTAGCTTC TTTGTGTGCAAAGCATCTCC 589 [1] 69
19 ATTGCACTTGAGGGATTCTTACC TTTGTGATATATTAATGGGCCAAG 496 [1] 67
20 TTGGCCCATTAATATATCACA TCTCACTCCAACTGTTATGGCTTA 594 [1] NA
21-1 AATTGCTGTTGCTCTCAGCC GAGTACATTCATCGCTGGGC 508 [1] 68
21-2 ACAAGCAGGAAATACCCGTG ACTGCAAACCACTTTCAGGC 501 [1] 68
22 AAAGCATAGAATATGTGGGAATT AGAAATTTGCCTCCATCAAA 584 [1] NA
23-1 AACCCTTGCTTTTATTGAGTTTC CAGGGCTTCCACACAGTCC 574 [1] NA
23-2 AAACTGTGGTGTTGACACGG TACAAGGCCAACACGATGAG 571 [1] 68
24 TGTGGGGATAGTGTAAATGCTTC TGCCGTCAGAACTCTGAAAC 403 [1] 68
25-26 TGGACTGCCTGTAAAAGTGG TGAACTTTTCCCCTTTGATG 450 [1] 66
27 CCTGTCTGTCGGGGGTATG TCTGCCTTCAATTCATTCCA 448 [1] 69
Key: HRM- High Resolution Melt. Oligonucleotide primers 16R and 17 F are new; they were designed specifically for High Resolution Melt analysis.
NA: Not Applicable – the fragments amplified were not included in the HRM assay, they were sequenced instead.
[1] refers to the source of the oligonucleotide primer sequences. bp - base pairs.
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HRM results, was used as the sole method of DICER1
analysis for exons 13, 20, 22 and the 5’ half of exon 23.
Intron-exon boundaries were included in all analyses.
Findings
Among the 43 probands, we identified 14 different single
nucleotide variants or polymorphisms, 12 of which have
been previously reported, but no likely deleterious vari-
ants; notably no mutations that were predicted to trun-
cate the protein were identified (Table 3).
TGCT account for 1 percent of all malignancies in
males, but are the most common cancer among young
men aged 15–35 years. Most germ cell tumors can be
classified as seminomas or non-seminomas, while asmall proportion are of mixed histology. Established risk
factors include cryptorochidism, previous diagnosis of
TGCT, subfertility and family history of TGCT
(reviewed in [17,18]).
Multiple epidemiological studies point toward a strong
genetic basis for TGCT susceptibility. A large Swedish
study estimates the genetic contribution of TGCT sus-
ceptibility to be about 25%, the third highest among can-
cers. Although familial aggregation of TGCT is rare with
only 1.4% of families having two or more first degree rel-
atives with the disease, multiple studies in different pop-
ulations have shown that sons of an affected father are
at 4–6 fold increased risk of developing TGCT while
brothers of an affected male are at 8–10 fold increased
risk, a familial relative risk that is much higher than
Table 3 DICER1 variants observed in 43 TGCT probands studied 14 samples had no SNPs
Variant Predicted function Number of cases
c.1377-25 T > A Likely non-pathogenic Previously reported 1****
c.1509 + 32A > G, rs144973109 Likely non-pathogenic Previously reported 2
c.1907 + 43C > T, rs11624081 Likely non-pathogenic Previously reported 6*
c.1907 + 105C > T, rs2275182 Likely non-pathogenic Previously reported 2*
c.1935G > A p.P645P, rs61751177 Likely non-pathogenic Previously reported 2§
c.2041-91A > G, rs2297730 Likely non-pathogenic Previously reported 6, 1***, 1§§§
c.2116 + 59insA Likely non-pathogenic Novel 1***
c.2116 + 65A > T, rs187825570 Likely non-pathogenic Previously reported 1**
c.2804 + 62C > T, rs117996122 Likely non-pathogenic Previously reported 1§§
c.2805-129G > A Likely non-pathogenic Novel 1
c.2997 T > G p. L999L, rs12018992 Likely non-pathogenic Previously reported 1***
c.3093 + 178 T > C, rs17091820 Likely non-pathogenic Previously reported 1***
c.5145C > T p. L1715L, rs139500905 Likely non-pathogenic Previously reported 1
c.*88 T > A, rs13078 Likely non-pathogenic Previously reported 15
* one case has s11624081 in addition to this variant, and another has both rs61751177 and s11624081 (i.e. this person carries 3 variants).
** has both rs2297730 and rs13078 in addition to this variant.
*** has rs2297730, rs17091820, rs12018992 and c.2116 + 59insA (i.e. this person carries 4 variants).
**** has rs144973109 and rs2297730 in addition to this variant.
§ one case has both rs2275182 and rs11624081 in addition to this variant (i.e. this person carries 3 variants), and one case has rs13078 in addition to this variant.
§§ has rs13078 in addition to this variant.
§§§ has rs13078 in addition to this variant.
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with an incidence five times higher in Caucasian males
than in African-Americans (as reviewed by Rapley and
Nathanson) [19].
A genome-wide linkage search for susceptibility loci
initially identified a region on Xp27 as a possible candi-
date, however this finding was not replicated in an inde-
pendent data set, the results of which suggested that no
single highly penetrant allele is responsible for a sub-
stantial proportion of familial TGCT [20]. Candidate-
gene analysis of a “gr/gr” deletion on the Y chromosome
known to cause infertility, was found to be associated
with a 2–3 fold risk of developing TGCT [21], however
the deletion was present in only 2% of TGCT patients
unselected for family history, explaining just 0.5% of the
excess familial risk [22]. Other candidate-gene analyses
have suggested associations with genes involved in im-
mune and hormone regulation, however these findings
have not been confirmed. Stronger evidence has come
from recent genome-wide association studies that have
identified six susceptibility loci implicating KITLG,
SPRY4, BAK1, TERT, ATF7IP and DMRT1 in disease
pathogenesis. Nevertheless, these six loci together with
the “gr/gr” deletion account for less than 15% of the ex-
cess familial risk, suggesting that many more risk alleles
remain unaccounted for (reviewed in [19,22]). A recent
study suggested a possible role for de novo germline
copy number variants (CNVs); such variants were seen
in 7% of 43 TGCT trios, greater than the expectedbackground rate of CNVs [23]. With these results in
mind, whole exome/genome sequencing studies, focus-
ing on large series of familial TGCTs is likely to be the
next step in efforts to understand the genetic basis of
TGCT.
The findings reported herein, when combined with the
previously reported studies discussed above, suggest that
neither germ-line nor somatic DICER1 mutations are
commonly associated with TGCT. These results strongly
suggest that TGCTs do not fall within the spectrum of
diseases associated with germ-line DICER1 mutations
and thus clinical screening for such cancers is not
warranted in DICER1 mutation carriers.
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